Key Events This Week
27 Jan: Stock hits 52-week low at Rs.375 amid ongoing downtrend
29 Jan: New 52-week low recorded at Rs.374.95; Q3 FY26 results reveal mounting losses
30 Jan: Week closes at Rs.408.20, up 4.09% for the week
Feb 06
BSE+NSE Vol: 2.75 k
Commodity Chemicals
INR 582 Cr (Micro Cap)
NA (Loss Making)
39
0.30%
0.29
0.82%
1.53
Latest dividend: 1.2 per share ex-dividend date: Sep-04-2025

Chemfab Alkalis Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 07 July 2025, reflecting a shift in the company’s outlook. However, the analysis and financial metrics discussed here are based on the stock’s current position as of 04 February 2026, providing investors with the latest insights into its performance and prospects.
Read full news article
27 Jan: Stock hits 52-week low at Rs.375 amid ongoing downtrend
29 Jan: New 52-week low recorded at Rs.374.95; Q3 FY26 results reveal mounting losses
30 Jan: Week closes at Rs.408.20, up 4.09% for the week
Chemfab Alkalis Ltd's latest financial results for Q3 FY26 indicate a company facing significant operational challenges. The net sales for the quarter were reported at ₹68.14 crores, reflecting a decline of 18.51% year-on-year and a sequential decrease of 11.00%. This marks the third consecutive quarter of falling sales, with cumulative revenue down 25.56% over the last two quarters. The company's net profit was a loss of ₹4.45 crores, a stark contrast to a profit of ₹3.64 crores in the same quarter last year, representing a substantial year-on-year decline. The operating margin also contracted sharply to 2.85%, down from 14.24% a year ago, indicating severe pricing pressures or cost inflation that the company has struggled to manage. Additionally, the operating profit before depreciation, interest, tax, and other income (PBDIT excluding other income) fell to ₹1.94 crores, the lowest in seven quarters, hi...
Read full news articleSubmission of newspaper clippings on publication of unaudited financial results for the quarter and nine months ended 31st December 2025
Submission of investor presentation for the quarter ended 31st December 2025
The Board meeting held today i.e. 28th January 2026 has approved the Un-Audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31° December 2025 as recommended by the Audit committee at its meeting held earlier in the day.
No Upcoming Board Meetings
Chemfab Alkalis Ltd has declared 12% dividend, ex-date: 04 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Promoters
None
Held by 2 Schemes (0.07%)
Held by 2 FIIs (0.08%)
Dr Rao Holdings Pte Ltd (47.04%)
V. M. Srinivasan (1.8%)
21.56%
QoQ Growth in quarter ended Dec 2025 is -11.00% vs -16.36% in Sep 2025
QoQ Growth in quarter ended Dec 2025 is -121.39% vs -178.82% in Sep 2025
Growth in half year ended Sep 2025 is 6.10% vs -0.14% in Sep 2024
Growth in half year ended Sep 2025 is 50.00% vs -97.39% in Sep 2024
YoY Growth in nine months ended Dec 2025 is -2.40% vs -1.20% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -274.55% vs -89.29% in Dec 2024
YoY Growth in year ended Mar 2025 is 2.16% vs -1.23% in Mar 2024
YoY Growth in year ended Mar 2025 is -126.37% vs -59.24% in Mar 2024